Please Wait.....
Report
Middle East & Africa Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher's Disease, MPS-1 & IV, Cancer, Alzheimer's Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]
Market Report I 2022-11-18 I 197 Pages I The Insight Partners
The glycomic therapeutics market in the Middle East & Africa is expected to grow from US$ 5.79 billion in 2022 to US$ 12.85 billion by 2028; it is estimated to grow at a CAGR of 13.1% from 2022 to 2028.
New Tools in Glycomics Research to Drive Market Growth
Glycomics has the potential to pave the way for innovative treatment approaches by enhancing the characterization of molecules crucial for the development of diseases. It can be a substantial addition to technologies used in genomes and proteomics. Comparative glycomics will be essential for identifying the glycans that cause the disease. There is a rising number of studies that will provide vital information on the relationship between clinical outcomes and glycomic anomalies. Immunohistochemistry (IHC), Liquid Chromatography-Mass Spectrometry (LC-MS), and high-throughput fluorescence flow cytometry have been used to distinguish cell populations using glycoproteins. These are among the important technologies utilized to advance glycomics. LC-MS can provide structural details about glycoconjugates by separating several glycoprotein isoforms from a single protein species. Unbiased surveys of cellular proteomes are now available due to high-throughput MS-based proteomics, and the method is swiftly applied to glycomics.
Structural reference databases are quickly emerging to close the gap between the variety and complexity of glycan structures. Identification of disease-related glycoconjugates by LC-MC, which employs antibody-based capture to view glycoconjugate expression with cell-staining or fluorescence, can be used to assess or validate IHC. Targeting complete cells rather than tissue fragments, immunocytochemistry (ICC) reveals glycoprotein expression patterns at the cellular level utilizing the same imaging techniques as IHC. It will be possible to witness new aspects of glycomics, such as thorough characterization of metabolic junctions and pathways, by modifying IHC and ICC to concentrate on additional glycoconjugates, including glycolipids. Tandem or multi-technology procedures, such as MS-IHC, would provide the analytical ability to labs to handle the glycoconjugates complexity and improve glycoconjugate diagnosis. The clinical applications of glycomics are catching up to those of genomics and proteomics due to the development of new high-throughput methods to study the structure and expression of glycans and ongoing innovation in glycan biomarkers and therapies. Integrating glycomics will revolutionize precision medicine into an extensive omics strategy, providing new information on the interactions between genes, proteins, and glycans. The combination of omics data with digital health platforms has the potential to improve clinical trials and provides knowledge to researchers and doctors regarding illness. Owing to the rising scientific discoveries, widespread acceptance of glycomics and personalized medicine will necessitate significant changes in regulatory and reimbursement procedures and legislative privacy laws. Thus, customized healthcare challenges will be met and overcome with the assurance that the research behind glycomic therapeutics is adequate and that the practice of medicine is evidence-based.
Growing evidence of glycomics role in human health highlights the need to integrate glycomics into precision medicine. Cell surface expression of glycoconjugates determines in vivo recognition and in vitro interactions. Microorganisms that perform important functions for their hosts, such as food digestion and vitamin synthesis and absorption, utilize complex carbohydrates to tell immune cells that they are not harmful. Pathogens that cause deadly diseases, such as tuberculosis and malaria, use similar strategies to evade attacks by the immune system.
Market Overview
The UAE, Saudi Arabia, and South Africa are the three major countries in the Middle East & South Africa. Saudi Arabia was the largest market for glycomic therapeutics in this region in 2022. The market for glycomic therapeutics in the Middle East & Africa is anticipated to grow at a CAGR of 14.2% during the forecast period; this growth is attributed to the rising prevalence of cancer and metabolic diseases and increasing government initiatives in terms of funding and healthcare-related policies.
Middle East & Africa Glycomic Therapeutics Market Revenue and Forecast to 2028 (US$ Billion)
Middle East & Africa Glycomic Therapeutics Market Segmentation
The Middle East & Africa glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.
Based on class, the Middle East & Africa glycomic therapeutics market is bifurcated into isolated and synthetic. The synthetic segment registered a larger market share in 2022. Based on structure, the Middle East & Africa glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2022. Based on indications, the Middle East & Africa glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher's disease, MPS-1 & IV, cancer, alzheimer's disease, influenza type A & B, and others. The influenza type a & b segment held the largest market share in 2022. Based on mode of action, the Middle East & Africa glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022. Based on country, the Middle East & Africa glycomic therapeutics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the market in 2022. Protalix Biotherapeutics; BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); Bayer AG; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd. are the leading companies operating in the glycomic therapeutics in the Middle East & Africa.
TABLE OF CONTENTS
1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Middle East & Africa Glycomic Therapeutics Market - By Class
1.3.2 Middle East & Africa Glycomic Therapeutics Market - By Structures
1.3.3 Middle East & Africa Glycomic Therapeutics Market - By Indications
1.3.4 Middle East & Africa Glycomic Therapeutics Market - By Mode of Action
1.3.5 Middle East & Africa Glycomic Therapeutics Market - By Country
2. Middle East & Africa Glycomic Therapeutics Market- Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Glycomic Therapeutics Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Middle East & Africa - PEST Analysis
4.3 Expert Opinion
5. Middle East & Africa Glycomic Therapeutics Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Wide Application in Various Disorders Followed by the Development of New Treatment Processes
5.1.2 Increasing Research and Development In the Field of Glycomic Therapeutics
5.2 Market Restraints
5.2.1 Shortage of Skilled Professionals and Lack of Research & Development laboratories in Developing Countries.
5.3 Market Opportunities
5.3.1 Wide Applications of Glycomics in Therapeutics
5.4 Future Trends
5.4.1 New Tools in Glycomics Research
5.5 Impact Analysis
6. Glycomic Therapeutics Market- Middle East & Africa Analysis
6.1 Middle East & Africa Glycomic Therapeutics Market Revenue Forecast and Analysis
6.1.1 Middle East & Africa : Glycomic Therapeutics Market Revenue and Forecasts to 2028, (US$ Million)
7. Middle East & Africa Glycomic Therapeutics Market Revenue and Forecast to 2028- by Class
7.1 Overview
7.2 Middle East & Africa Glycomic Therapeutics Market, By Class 2022 & 2028 (%)
7.2.1 Middle East & Africa: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
7.3 Isolated
7.3.1 Overview
7.3.2 Middle East & Africa Isolated Revenue and Forecast to 2028 (US$ Million)
7.4 Synthetic
7.4.1 Overview
7.4.2 Middle East & Africa Synthetic - Revenue and Forecast to 2028 (US$ Million)
8. Middle East & Africa Glycomics Therapeutics Market Analysis and Forecasts To 2028 - By Indication
8.1 Overview
8.2 Middle East & Africa Glycomics Market, By Indication 2022 & 2028 (%)
8.2.1 Middle East & Africa: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
8.3 Thrombosis and Chemoprophylaxis
8.3.1 Overview
8.3.2 Middle East & Africa Thrombosis and chemoprophylaxis Revenue and Forecast to 2028 (US$ Million)
8.4 Anaemia
8.4.1 Overview
8.4.2 Middle East & Africa Anaemia Revenue and Forecast to 2028 (US$ Million)
8.5 Anti-adhesive and Anti-inflammatory
8.5.1 Overview
8.5.2 Middle East & Africa Anti-adhesive and Anti-inflammatory Revenue and Forecast to 2028 (US$ Million)
8.6 Cataract
8.6.1 Overview
8.6.2 Middle East & Africa Cataract Revenue and Forecast to 2028 (US$ Million)
8.7 Gaucher's diseases
8.7.1 Overview
8.7.2 Middle East & Africa Gaucher's diseases Revenue and Forecast to 2028 (US$ Million)
8.8 MPS-1 & IV
8.8.1 Overview
8.8.2 Middle East & Africa MPS-1 & IV Revenue and Forecast to 2028 (US$ Million)
8.9 Cancer
8.9.1 Overview
8.9.2 Middle East & Africa Cancer Revenue and Forecast to 2028 (US$ Million)
8.10 Alzheimer's
8.10.1 Overview
8.10.2 Middle East & Africa Alzheimer's Revenue and Forecast to 2028 (US$ Million)
8.11 Influenza Type A and B
8.11.1 Overview
8.11.2 Middle East & Africa Influenza Type A and B Revenue and Forecast to 2028 (US$ Million)
8.12 Others
8.12.1 Overview
8.12.2 Middle East & Africa Others Revenue and Forecast to 2028 (US$ Million)
9. Middle East & Africa Glycomic Therapeutics Market Revenue and Forecast to 2028 - by Structures
9.1 Overview
9.2 Middle East & Africa Glycomic Therapeutics Market, By Structures 2022 & 2028 (%)
9.2.1 Middle East & Africa: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
9.2.1.1 Middle East & Africa: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
9.2.1.2 Middle East & Africa: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
9.2.1.3 Middle East & Africa: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
9.2.1.4 Middle East & Africa: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
9.3 Glycoproteins
9.3.1 Overview
9.3.2 Middle East & Africa Glycoproteins - Market Revenue and Forecast to 2028 (US$ Million)
9.4 Targeting Sialic Acid
9.4.1 Overview
9.4.2 Middle East & Africa Targeting Sialic Acid - Market Revenue and Forecast to 2028 (US$ Million)
9.4.3 Zanamivir
9.4.3.1 Overview
9.4.3.2 Middle East & Africa Zanamivir - Market Revenue and Forecast to 2028 (US$ Million)
9.4.4 Oseltamivir
9.4.4.1 Overview
9.4.4.2 Middle East & Africa Oseltamivir - Market Revenue and Forecast to 2028 (US$ Million)
9.5 Proteoglycans
9.5.1 Overview
9.5.2 Middle East & Africa Proteoglycans - Market Revenue and Forecast to 2028 (US$ Million)
9.6 Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans
9.6.1 Overview
9.6.2 Middle East & Africa Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecast to 2028 (US$ Million)
9.7 Targeting Glycosaminoglycans
9.7.1 Overview
9.7.2 Middle East & Africa Targeting Glycosaminoglycans - Market Revenue and Forecast to 2028 (US$ Million)
9.7.3 Heparin
9.7.3.1 Overview
9.7.3.2 Middle East & Africa Heparin - Market Revenue and Forecast to 2028 (US$ Million)
9.7.4 Hyaluronan (HA)
9.7.4.1 Overview
9.7.4.2 Middle East & Africa Hyaluronan (HA)- Market Revenue and Forecast to 2028 (US$ Million)
9.7.5 Laronidase
9.7.5.1 Overview
9.7.5.2 Middle East & Africa Laronidase - Market Revenue and Forecast to 2028 (US$ Million)
9.7.6 Galsulfase (Naglazyme)
9.7.6.1 Overview
9.7.6.2 Middle East & Africa Galsulfase (Naglazyme) - Market Revenue and Forecast to 2028 (US$ Million)
9.7.7 Hyaluronidase (Cumulase)
9.7.7.1 Overview
9.7.7.2 Middle East & Africa Hyaluronidase (Cumulase) - Market Revenue and Forecast to 2028 (US$ Million)
9.7.8 Others
9.7.8.1 Overview
9.7.8.2 Middle East & Africa Others - Market Revenue and Forecast to 2028 (US$ Million)
9.8 Targeting Glycosphingolipids
9.8.1 Overview
9.8.2 Middle East & Africa Targeting Glycosphingolipids - Market Revenue and Forecast to 2028 (US$ Million)
9.8.3 Imiglucerase (Cerezyme)
9.8.3.1 Overview
9.8.3.2 Middle East & Africa Imiglucerase (Cerezyme)- Market Revenue and Forecast to 2028 (US$ Million)
9.8.3.3 Agalsidase (Fabrazyme)
9.8.3.3.1 Overview
9.8.3.3.2 Middle East & Africa Agalsidase (Fabrazyme) - Market Revenue and Forecast to 2028 (US$ Million)
9.8.3.4 N-butyl-deoxynojirimycin (DNJ)
9.8.3.4.1 Overview
9.8.3.4.2 Middle East & Africa N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecast to 2028 (US$ Million)
9.8.4 Others
9.8.4.1 Overview
9.8.4.2 Middle East & Africa Others - Market Revenue and Forecast to 2028 (US$ Million)
9.9 Others
9.9.1 Overview
9.9.2 Middle East & Africa Others - Market Revenue and Forecast to 2028 (US$ Million)
9.9.3 Acarbose
9.9.3.1 Overview
9.9.3.2 Middle East & Africa Acarbose - Market Revenue and Forecast to 2028 (US$ Million)
9.9.3.3 Alglucosidase Alfa (Myozyme)
9.9.3.3.1 Overview
9.9.3.3.2 Middle East & Africa Alglucosidase Alfa (Myozyme) - Market Revenue and Forecast to 2028 (US$ Million)
9.9.3.4 Allosamidin
9.9.3.4.1 Overview
9.9.3.4.2 Middle East & Africa Allosamidin - Market Revenue and Forecast to 2028 (US$ Million)
9.9.4 Others
9.9.4.1 Overview
9.9.4.2 Middle East & Africa Others - Market Revenue and Forecast to 2028 (US$ Million)
10. Middle East & Africa Glycomic Therapeutics Market Revenue and Forecast to 2028 - by Mode of Action
10.1 Overview
10.2 Middle East & Africa Glycomic Therapeutics Market, By Mode of Action 2022 & 2028 (%)
10.2.1 Middle East & Africa: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
10.3 Inhibits Neuraminidase
10.3.1 Overview
10.3.2 Middle East & Africa Inhibits Neuraminidase - Market Revenue and Forecast to 2028 (US$ Million)
10.4 Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate
10.4.1 Overview
10.4.2 Middle East & Africa Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecast to 2028 (US$ Million)
10.5 Erythropoietin And Enzyme Replacement Therapy (ERT)
10.5.1 Overview
10.5.2 Middle East & Africa Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecast to 2028 (US$ Million)
10.6 Tissue Plasminogen Activator
10.6.1 Overview
10.6.2 Middle East & Africa Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US$ Million)
10.7 Inhibits Glucosylceramide Synthase
10.7.1 Overview
10.7.2 Middle East & Africa Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US$ Million)
10.8 Interleukin 1 And 2 And 3
10.8.1 Overview
10.8.2 Middle East & Africa Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)
10.9 Beta And Gamma Interferons
10.9.1 Overview
10.9.2 Middle East & Africa Beta And Gamma Interferons- Market Revenue And Forecasts To 2028 (US$ Million)
10.10 Others
10.10.1 Overview
10.10.2 Middle East & Africa Others- Market Revenue And Forecasts To 2028 (US$ Million)
11. Middle East & Africa Glycomic Therapeutics Market Revenue and Forecasts to 2028 - Country Analysis
11.1 Middle East & Africa: Glycomic Therapeutics Market
11.1.1 Overview
11.1.2 Middle East & Africa: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)
11.1.2.1 Saudi Arabia: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.1.2.1.1 Overview
11.1.2.1.2 Saudi Arabia: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.1.3 Saudi Arabia: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.2.1.4 Saudi Arabia: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.2.1.4.1 Saudi Arabia: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.2.1.4.2 Saudi Arabia: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.2.1.4.3 Saudi Arabia: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.2.1.4.4 Saudi Arabia: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.2.1.5 Saudi Arabia: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.2.1.6 Saudi Arabia: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.2.2 UAE: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.1.2.2.1 Overview
11.1.2.2.2 UAE: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.2.3 UAE: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.2.2.4 UAE: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.2.2.4.1 UAE: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.2.2.4.2 UAE: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.2.2.4.3 UAE: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.2.2.4.4 UAE: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.2.2.5 UAE: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.2.2.6 UAE: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.2.3 South Africa: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.1.2.3.1 Overview
11.1.2.3.2 South Africa: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.3.3 South Africa: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.2.3.4 South Africa: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.2.3.4.1 South Africa: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.2.3.4.2 South Africa: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.2.3.4.3 South Africa: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.2.3.4.4 South Africa: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.2.3.5 South Africa: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.2.3.6 South Africa: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.2.4 Rest of Middle East and Africa: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.1.2.4.1 Overview
11.1.2.4.2 Rest of MEA: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.4.3 Rest of MEA: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.2.4.4 Rest of MEA: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.2.4.4.1 Rest of MEA: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.2.4.4.2 Rest of MEA: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.2.4.4.3 Rest of MEA: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.2.4.4.4 Rest of MEA: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.2.4.5 Rest of MEA: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.2.4.6 Rest of MEA: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
12. Middle East & Africa Glycomic Therapeutics Market -Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Glycomic Therapeutics Market (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 Protalix Biotherapeutics
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 BioMarin Pharmaceutical Inc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Genzyme Corporation (Sanofi)
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bayer AG
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 GlaxoSmithKline plc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 F. Hoffmann-La Roche Ltd
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms in Glycomic Therapeutics Market
LIST OF TABLES
Table 1. Middle East & Africa: Glycomic Therapeutics Market Revenue and Forecasts to 2028, (US$ Million).
Table 2. Middle East & Africa Glycomic Therapeutics Market, by C lass - Revenue and Forecast to 2028 (US$ Million)
Table 3. Middle East & Africa Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (USD Million)
Table 4. Middle East & Africa Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (USD Million)
Table 5. Middle East & Africa Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (USD Million)
Table 6. Middle East & Africa Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (USD Million)
Table 7. Middle East & Africa Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (USD Million)
Table 8. Middle East & Africa Glycomic Therapeutics Market, by Others- Revenue and Forecast to 2028 (USD Million)
Table 9. Middle East & Africa Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (USD Million)
Table 10. Saudi Arabia Glycomic Therapeutics Market, by Class - Revenue and Forecast to 2028 (US$ Million)
Table 11. Saudi Arabia Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (US$ Million)
Table 12. Saudi Arabia Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (US$ Million)
Table 13. Saudi Arabia Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (US$ Million)
Table 14. Saudi Arabia Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (US$ Million)
Table 15. Saudi Arabia Glycomic Therapeutics Market, by Others - Revenue and Forecast to 2028 (US$ Million)
Table 16. Saudi Arabia Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 17. Saudi Arabia Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (US$ Million)
Table 18. UAE Glycomic Therapeutics Market, by Class - Revenue and Forecast to 2028 (US$ Million)
Table 19. UAE Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (US$ Million)
Table 20. UAE Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (US$ Million)
Table 21. UAE Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (US$ Million)
Table 22. UAE Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (US$ Million)
Table 23. UAE Glycomic Therapeutics Market, by Others - Revenue and Forecast to 2028 (US$ Million)
Table 24. UAE Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 25. UAE Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (US$ Million)
Table 26. South Africa Glycomic Therapeutics Market, by Class - Revenue and Forecast to 2028 (US$ Million)
Table 27. South Africa Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (US$ Million)
Table 28. South Africa Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (US$ Million)
Table 29. South Africa Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (US$ Million)
Table 30. South Africa Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (US$ Million)
Table 31. South Africa Glycomic Therapeutics Market, by Others - Revenue and Forecast to 2028 (US$ Million)
Table 32. South Africa Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 33. South Africa Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (US$ Million)
Table 34. Rest of MEA Glycomic Therapeutics Market, by Class - Revenue and Forecast to 2028 (US$ Million)
Table 35. Rest of MEA Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (US$ Million)
Table 36. Rest of MEA Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (US$ Million)
Table 37. Rest of MEA Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (US$ Million)
Table 38. Rest of MEA Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (US$ Million)
Table 39. Rest of MEA Glycomic Therapeutics Market, by Others - Revenue and Forecast to 2028 (US$ Million)
Table 40. Rest of MEA Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 41. Rest of MEA Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (US$ Million)
Table 42. Organic Developments in the Glycomic Therapeutics Market
Table 43. Inorganic Developments in the Glycomic Therapeutics Market
Table 44. Glossary of Terms in Glycomic Therapeutics Market
LIST OF FIGURES
Figure 1. Middle East & Africa Glycomic Therapeutics Market Segmentation
Figure 2. Middle East & Africa Glycomic Therapeutics Market, By Country
Figure 3. Middle East & Africa Glycomic Therapeutics Market Overview
Figure 4. Synthetic Segment Held Largest Share of Class Segment in Middle East & Africa Glycomic Therapeutics Market
Figure 5. UAE is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Middle East & Africa: PEST Analysis
Figure 7. Middle East & Africa Glycomic Therapeutics Market Impact Analysis of Driver and Restraints
Figure 8. Middle East & Africa Glycomics market - Revenue Forecast and Analysis - 2020- 2028
Figure 9. Middle East & Africa Glycomic Therapeutics Market, by Class 2022 & 2028 (%)
Figure 10. Middle East & Africa Isolated Revenue and Forecasts to 2028 (US$ Million)
Figure 11. Middle East & Africa Synthetic - Revenue and Forecasts to 2028 (US$ Million)
Figure 12. Middle East & Africa Glycomics Market, by Indication 2022 & 2028 (%)
Figure 13. Middle East & Africa Thrombosis and chemoprophylaxis Revenue and Forecasts to 2028 (US$ Million)
Figure 14. Middle East & Africa Anaemia Revenue and Forecasts to 2028 (US$ Million)
Figure 15. Middle East & Africa Anti-adhesive and Anti-inflammatory Revenue and Forecasts to 2028 (US$ Million)
Figure 16. Middle East & Africa Cataract Revenue and Forecasts to 2028 (US$ Million)
Figure 17. Middle East & Africa Gaucher's diseases Revenue and Forecasts to 2028 (US$ Million)
Figure 18. Middle East & Africa MPS-1 & IV Revenue and Forecasts to 2028 (US$ Million)
Figure 19. Middle East & Africa Cancer Revenue and Forecasts to 2028 (US$ Million)
Figure 20. Middle East & Africa Alzheimer's Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Middle East & Africa Influenza Type A and B Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Middle East & Africa Others Revenue and Forecasts to 2028 (US$ Million)
Figure 23. Middle East & Africa Glycomic Therapeutics Market, by Structures 2022 & 2028 (%)
Figure 24. Middle East & Africa Glycoproteins - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 25. Middle East & Africa Targeting Sialic Acid - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 26. Middle East & Africa Zanamivir - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 27. Middle East & Africa Oseltamivir - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 28. Middle East & Africa Proteoglycans - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 29. Middle East & Africa Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 30. Middle East & Africa Targeting Glycosaminoglycans - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 31. Middle East & Africa Heparin - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 32. Middle East & Africa Hyaluronan (HA)- Market Revenue and Forecasts to 2028 (US$ Million)
Figure 33. Middle East & Africa Laronidase - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 34. Middle East & Africa Galsulfase (Naglazyme) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 35. Middle East & Africa Hyaluronidase (Cumulase) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 36. Middle East & Africa Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 37. Middle East & Africa Targeting Glycosphingolipids - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 38. Middle East & Africa Imiglucerase (Cerezyme - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 39. Middle East & Africa Agalsidase (Fabrazyme) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 40. Middle East & Africa N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 41. Middle East & Africa Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 42. Middle East & Africa Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 43. Middle East & Africa Acarbose - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 44. Middle East & Africa Alglucosidase Alfa (Myozyme) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 45. Middle East & Africa Allosamidin - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 46. Middle East & Africa Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 47. Middle East & Africa Glycomic Therapeutics Market, by Mode of Action 2022 & 2028 (%)
Figure 48. Middle East & Africa Inhibits Neuraminidase - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 49. Middle East & Africa Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 50. Middle East & Africa Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 51. Middle East & Africa Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 52. Middle East & Africa Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 53. Middle East & Africa Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)
Figure 54. Middle East & Africa Beta And Gamma Interferons - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 55. Middle East & Africa Others - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 56. Middle East & Africa Glycomic Therapeutics Market Revenue Overview, by Country, 2022 (US$ Million)
Figure 57. Middle East & Africa: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)
Figure 58. Saudi Arabia: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 59. UAE: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 60. South Africa: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 61. Rest of MEA: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 62. Growth Strategies in the Glycomic Therapeutics Market (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security